A 72-year-old woman with a mechanical mitral valve prosthesis on long-term warfarin presents to the emergency department with a 2-week history of epistaxis, gum bleeding, and a single episode of melena. Her INR is 9.2 (target 2.5–3.5). Which investigation is most appropriate to assess the risk of bleeding and guide reversal strategy?

Explanation

## Clinical Context: Warfarin Overdose with Bleeding The patient presents with **over-anticoagulation** (INR 9.2, well above therapeutic range) and **active bleeding** (epistaxis, gum bleeding, melena). The clinical question is: which coagulation panel best assesses the bleeding risk and guides reversal therapy? ### Coagulation Assessment in Warfarin Toxicity **Key Point:** In warfarin overdose with bleeding, the **PT/INR, aPTT, and platelet count** form the **core coagulation screen** that: 1. **Quantifies the degree of anticoagulation** via PT/INR 2. **Detects consumptive coagulopathy** (prolonged aPTT, low fibrinogen, low platelets) if bleeding is severe 3. **Excludes thrombocytopenia** as a contributor to bleeding 4. **Guides reversal dosing** — the PT/INR directly determines the dose of vitamin K₁ and fresh frozen plasma (FFP) or prothrombin complex concentrate (PCC) ### Why This Combination? ```mermaid flowchart TD A["Warfarin overdose + bleeding"]:::outcome --> B{"Assess coagulation status"}:::decision B --> C["PT/INR"]:::action B --> D["aPTT"]:::action B --> E["Platelet count"]:::action C --> F["Quantifies warfarin effect"]:::outcome D --> G["Detects consumptive coagulopathy"]:::outcome E --> H["Excludes thrombocytopenia"]:::outcome F --> I["Guides vitamin K + PCC/FFP dosing"]:::action G --> I H --> I ``` ### Interpretation in This Case | Finding | Implication | |---|---| | **PT/INR = 9.2** | Severe warfarin effect; requires reversal | | **aPTT** | If prolonged → consumptive coagulopathy or DIC; if normal → isolated PT prolongation | | **Platelets** | If low → DIC or drug-induced thrombocytopenia; if normal → isolated coagulation defect | **High-Yield:** The **PT/INR is the single most important test** because it directly determines the **dose of vitamin K₁ and PCC/FFP**: - INR 4.5–10 with no bleeding: vitamin K₁ alone - INR >10 or with bleeding: vitamin K₁ + **PCC (preferred) or FFP** ### Why Other Investigations Are Suboptimal **Thrombin Time (TT) & Fibrinogen:** - TT is prolonged in warfarin overdose but is **non-specific** (also prolonged in hypofibrinogenemia, FDP elevation, heparin effect) - Fibrinogen is normal in uncomplicated warfarin toxicity; only abnormal if DIC is present - Does NOT guide reversal dosing **Bleeding Time & Platelet Aggregation:** - Bleeding time is **obsolete** and has been removed from modern coagulation panels - Platelet aggregation studies are for **platelet function disorders**, not warfarin toxicity - Warfarin does NOT affect platelet function **Factor V & Factor II Assay:** - Specific but **not practical** in acute bleeding; results take hours - PT/INR already reflects the deficiency of factors II, VII, IX, X - Does NOT guide immediate reversal **Clinical Pearl:** In warfarin bleeding, always obtain **PT/INR + aPTT + CBC** as the minimum coagulation screen. The PT/INR guides reversal; aPTT and platelet count detect consumptive coagulopathy or other bleeding diatheses. [cite:KD Tripathi 8e Ch 12; Harrison 21e Ch 297]